Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-05-11
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 1221
- Registration Number
- NCT00082433
- Locations
- 🇬🇧
Local Institution, Birmingham, West Midlands, United Kingdom
To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older
- Conditions
- Interventions
- First Posted Date
- 2004-04-30
- Last Posted Date
- 2014-10-09
- Target Recruit Count
- 62
- Registration Number
- NCT00082095
Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-04-28
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT00005649
- Locations
- 🇺🇸
PPD Development, Wilmington, North Carolina, United States
Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2008-08-21
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 438
- Registration Number
- NCT00081796
- Locations
- 🇨🇱
Las Condes, Santiago, Chile
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
- Conditions
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 3
- Registration Number
- NCT00081224
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-03-30
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- R-Pharm
- Target Recruit Count
- 752
- Registration Number
- NCT00080301
- Locations
- 🇬🇧
Local Institution, Newcastle-Upon-Tyne, Tyne And Wear, United Kingdom
Capecitabine in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- First Posted Date
- 2004-03-24
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Registration Number
- NCT00006023
- Locations
- 🇨🇭
Kantonsspital - Saint Gallen, Saint Gallen, Switzerland
🇨🇭Spitalzentrum Biel, Biel, Switzerland
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
- Conditions
- First Posted Date
- 2004-03-17
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00006812
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States
Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer
- First Posted Date
- 2004-03-15
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 51
- Registration Number
- NCT00003704
- Locations
- 🇺🇸
CentraCare Clinic, Saint Cloud, Minnesota, United States
🇨🇦Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer
- First Posted Date
- 2004-03-03
- Last Posted Date
- 2010-12-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 408
- Registration Number
- NCT00078572
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.